Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 353 articles:
HTML format
Text format



Single Articles


    May 2019
  1. ZUNIGA KB, Zhao S, Kenfield SA, Cedars B, et al
    Trends in complementary and alternative medicine use among patients with prostate cancer.
    J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336.
    PubMed     Text format     Abstract available


  2. GRIEBLING TL
    Re: Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen-Deprivation Therapy to Reduce Risk of Fragility Fractures.
    J Urol. 2019 May 10:10109701JU000055973645783.
    PubMed     Text format    


  3. GONTERO P, Marra G, Alessio P, Filippini C, et al
    Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.
    J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327.
    PubMed     Text format     Abstract available


  4. TANEJA SS
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    J Urol. 2019 May 7:101097JU0000000000000323. doi: 10.1097/JU.0000000000000323.
    PubMed     Text format    


  5. TANEJA SS
    Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    J Urol. 2019 May 7:10109701JU0000559603179075.
    PubMed     Text format    


  6. ATALA A
    Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
    J Urol. 2019 May 7:101097JU0000000000000330. doi: 10.1097/JU.0000000000000330.
    PubMed     Text format    


  7. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 May 7:10109701JU0000559616036260.
    PubMed     Text format    


  8. TOM MC, Nguyen JK, Luciano R, Mian OY, et al
    Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    J Urol. 2019 May 6:101097JU0000000000000316. doi: 10.1097/JU.0000000000000316.
    PubMed     Text format     Abstract available


  9. MORTEZAVI A, Krauter J, Gu DA, Sonderer J, et al
    Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound.
    J Urol. 2019 May 1:101097JU0000000000000298. doi: 10.1097/JU.0000000000000298.
    PubMed     Text format     Abstract available


  10. CARTER HB
    Editorial Comment.
    J Urol. 2019;201:922.
    PubMed     Text format    


    April 2019
  11. HAESE A, Trooskens G, Steyaert S, Hessels D, et al
    Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy.
    J Urol. 2019 Apr 26:101097JU0000000000000293. doi: 10.1097/JU.0000000000000293.
    PubMed     Text format     Abstract available


  12. JOHNSON DC, Kwok E, Ahn C, Pashchinskiy A, et al
    Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode-based Reimbursement Model.
    J Urol. 2019 Apr 22:101097JU0000000000000283. doi: 10.1097/JU.0000000000000283.
    PubMed     Text format     Abstract available


  13. DASKIVICH TJ, Thomas IC, Luu M, Shelton JB, et al
    External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Apr 22:101097JU0000000000000287. doi: 10.1097/JU.0000000000000287.
    PubMed     Text format     Abstract available


  14. TANEJA SS
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial.
    J Urol. 2019 Apr 8:10109701JU00005577560832916.
    PubMed     Text format    


  15. TANEJA SS
    Re: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Urol. 2019 Apr 8:101097JU0000000000000276. doi: 10.1097/JU.0000000000000276.
    PubMed     Text format    


  16. TEWARI AK, Taouli B
    Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness.
    J Urol. 2019 Apr 8:101097JU0000000000000272. doi: 10.1097/JU.0000000000000272.
    PubMed     Text format     Abstract available


  17. CEDARS BE, Washington SL 3rd, Cowan JE, Leapman M, et al
    STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER.
    J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271.
    PubMed     Text format     Abstract available


  18. SHOAG J, Liu D, Ma X, Oromendia C, et al
    MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  19. SANDHU HS, Mulholland DJ
    MP68-11 IDENTIFICATION OF INTERMEDIATE CELL POPULATIONS DURING TREATMENT INDUCED LINEAGE CONVERSION TO NEUROENDOCRINE PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  20. VELLKY J, Ricke W
    MP68-13 DDX3-MEDIATED TRANSLATIONAL REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER PROGRESSION.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  21. FAISAL F, Alshalalfa M, Davicioni E, Karnes RJ, et al
    MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  22. JAMASPISHVILI T, Patel P, Niu Y, Vidotto T, et al
    MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  23. ADSHEAD J, Oldfield F, Hadaschik B, Wouter Everaerts JA, et al
    MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


  24. RICHIE JP
    Re: Association between Vasectomy and Risk of Testicular Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:667-668.
    PubMed     Text format    


  25. TOSOIAN JJ, George AK
    Editorial Comment.
    J Urol. 2019;201:727.
    PubMed     Text format    


  26. HARPER BT, Dykes TE, Terris MK
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed     Text format    


  27. SAMMON J
    Editorial Comment.
    J Urol. 2019;201:733-734.
    PubMed     Text format    


  28. GRUBB R
    Editorial Comment.
    J Urol. 2019;201:740-741.
    PubMed     Text format    


  29. KEEGAN KA
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed     Text format    


  30. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:733.
    PubMed     Text format    


  31. CARROLL P, Schmidt B
    Editorial Comment.
    J Urol. 2019;201:820.
    PubMed     Text format    


  32. MARTIN C, Haaland B, Tward AE, Dechet C, et al
    Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making.
    J Urol. 2019;201:751-758.
    PubMed     Text format     Abstract available


    March 2019
  33. ATALA A
    Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth.
    J Urol. 2019 Mar 29:101097JU0000000000000251. doi: 10.1097/JU.0000000000000251.
    PubMed     Text format    


  34. RESNICK MJ
    Re: Risk of Prostate Cancer in Men Treated with 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Urol. 2019 Mar 29:10109701JU00005577312536940.
    PubMed     Text format    


  35. ATALA A
    Re: Targeting FOXA1-Mediated Repression of TGF-beta Signaling Suppresses Castration-Resistant Prostate Cancer Progression.
    J Urol. 2019 Mar 29:10109701JU000055773048240.
    PubMed     Text format    


  36. PAK S, Park SY, Shin TJ, You D, et al
    Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer.
    J Urol. 2019 Mar 27:101097JU0000000000000249. doi: 10.1097/JU.0000000000000249.
    PubMed     Text format     Abstract available


  37. TANEJA SS
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    J Urol. 2019 Mar 13:101097JU0000000000000231. doi: 10.1097/JU.0000000000000231.
    PubMed     Text format    


  38. AMINSHARIFI A, Simon R, Polascik TJ, Robertson CN, et al
    Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer.
    J Urol. 2019 Mar 5:101097JU0000000000000207. doi: 10.1097/JU.0000000000000207.
    PubMed     Text format     Abstract available


  39. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    The ratio of the number of biopsy specimens to prostate volume (biopsy density) > 1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate.
    J Urol. 2019 Mar 5:101097JU0000000000000204. doi: 10.1097/JU.0000000000000204.
    PubMed     Text format     Abstract available


  40. WANG CS, Jhan JH, Li CC
    Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Po
    J Urol. 2019;201:627-628.
    PubMed     Text format    


  41. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
    J Urol. 2019;201:528-534.
    PubMed     Text format     Abstract available


  42. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
    J Urol. 2019;201:510-519.
    PubMed     Text format     Abstract available


  43. MIRAK SA, Shakeri S, Bajgiran AM, Felker ER, et al
    Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS version 2 Category and Staging with Whole Mount Histopathology Correlation.
    J Urol. 2019;201:496-502.
    PubMed     Text format     Abstract available


  44. LI-SHENG CHEN S, Ching-Yuan Fann J, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
    J Urol. 2019;201:486-495.
    PubMed     Text format     Abstract available


  45. ATALA A
    Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions.
    J Urol. 2019;201:447.
    PubMed     Text format    


  46. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:446-447.
    PubMed     Text format    


  47. TANEJA SS
    Re: A Multicentre Study of 5-Year Outcomes following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    J Urol. 2019;201:443-444.
    PubMed     Text format    


  48. TANEJA SS
    Re: Association between Prostate Magnetic Resonance Imaging and Observation for Low-Risk Prostate Cancer.
    J Urol. 2019;201:443.
    PubMed     Text format    


  49. HELFAND BT
    Editorial Comment.
    J Urol. 2019;201:494.
    PubMed     Text format    


  50. EPSTEIN J
    Editorial Comment.
    J Urol. 2019;201:540.
    PubMed     Text format    


  51. MORASH C
    Editorial Comment.
    J Urol. 2019;201:527.
    PubMed     Text format    


  52. ABDI H, Breau RH
    Editorial Comment.
    J Urol. 2019;201:518.
    PubMed     Text format    


  53. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:509.
    PubMed     Text format    


    February 2019
  54. FEI B, Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo O, et al
    Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
    J Urol. 2019 Feb 28:101097JU0000000000000200. doi: 10.1097/JU.0000000000000200.
    PubMed     Text format     Abstract available


  55. TAN N, Bavadian N, Calais J, Oyoyo U, et al
    Imaging of PSMA-targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence After Definitive Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2019 Feb 25:101097JU0000000000000198. doi: 10.1097/JU.0000000000000198.
    PubMed     Text format     Abstract available


  56. GREENLAND NY, Zhang L, Cowan JE, Carroll PR, et al
    Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000175. doi: 10.1097/JU.0000000000000175.
    PubMed     Text format     Abstract available


  57. STOVSKY M, Klein EA, Chait A, Manickam K, et al
    Clinical Validation of IsoPSA, a Single Parameter, Structure-Based Assay for Improved Detection of High-Grade Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000185. doi: 10.1097/JU.0000000000000185.
    PubMed     Text format     Abstract available


  58. GAFFNEY C, Golan R, Cantu MD, Scognamiglio T, et al
    The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
    J Urol. 2019 Feb 12:101097JU0000000000000170. doi: 10.1097/JU.0000000000000170.
    PubMed     Text format     Abstract available


  59. TANEJA SS
    Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000169.
    PubMed     Text format    


  60. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554059.66296.
    PubMed     Text format    


  61. STEFANOVA V, Buckley R, Flax S, Spevack L, et al
    Transperineal prostate biopsies under local anesthetic: Experience with 1287 patients Prostate cancer detection rate, complications and patient tolerability.
    J Urol. 2019 Feb 8:101097JU0000000000000156. doi: 10.1097/JU.0000000000000156.
    PubMed     Text format     Abstract available


  62. DAMODARAN S, Lang JM, Jarrard DF
    Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000117.
    PubMed     Text format     Abstract available


  63. ATALA A
    Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554005.76376.
    PubMed     Text format    


  64. ATALA A
    Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554004.38258.
    PubMed     Text format    


  65. GRIEBLING TL
    Re: Localised Prostate Cancer in Elderly Men Aged 80-89 Years, Findings from a Population-Based Registry.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553998.44096.
    PubMed     Text format    


  66. GRIEBLING TL
    Re: Alzheimer's Disease is Associated with Prostate Cancer: .
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553997.66966.
    PubMed     Text format    


  67. DAS S, Salami SS, Spratt DE, Kaffenberger SD, et al
    Bringing prostate cancer germline genetics into clinical practice.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000137.
    PubMed     Text format     Abstract available


  68. ZELEFSKY MJ, Goldman DA, Reuter V, Kollmeier M, et al
    Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000110.
    PubMed     Text format     Abstract available


  69. FALAGARIO UG, Beksac AT, Martini A, Cumarasamy S, et al
    Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
    J Urol. 2019 Feb 4. doi: 10.1097/JU.0000000000000134.
    PubMed     Text format     Abstract available


  70. ATALA A
    Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis.
    J Urol. 2019;201:230.
    PubMed     Text format    


  71. ATALA A
    Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer.
    J Urol. 2019;201:230.
    PubMed     Text format    


  72. TANEJA SS
    Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    J Urol. 2019;201:228.
    PubMed     Text format    


  73. TANEJA SS
    Re: Histologic Findings Associated with False Positive Multiparametric Magnetic Resonance Imaging Performed for Prostate Cancer Detection.
    J Urol. 2019;201:227-228.
    PubMed     Text format    


  74. SIEGEL C
    Re: Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    J Urol. 2019;201:208.
    PubMed     Text format    


  75. TILKI D
    Editorial Comment.
    J Urol. 2019;201:340.
    PubMed     Text format    


  76. SCARSBROOK A
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed     Text format    


  77. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed     Text format    


  78. THOMPSON JE, Stricker PD
    Editorial Comment.
    J Urol. 2019;201:306-307.
    PubMed     Text format    


  79. CARROLL P
    Editorial Comment.
    J Urol. 2019;201:298-299.
    PubMed     Text format    


  80. CHUA MLK
    Editorial Comment.
    J Urol. 2019;201:291.
    PubMed     Text format    


  81. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:290-291.
    PubMed     Text format    


  82. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:277.
    PubMed     Text format    


  83. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:276.
    PubMed     Text format    


  84. MOSES KA
    Editorial Comment.
    J Urol. 2019;201:267.
    PubMed     Text format    


  85. EGGENER S
    Editorial Comment.
    J Urol. 2019;201:266-267.
    PubMed     Text format    


  86. PIERRARD V, Lebdai S, Kleinclauss F, Azzouzi AR, et al
    Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
    J Urol. 2019;201:315-321.
    PubMed     Text format     Abstract available


  87. KIRMIZ S, Qi J, Babitz SK, Linsell S, et al
    Grade Groups Provide Improved Predictions of Pathological and Early Oncologic Outcomes Compared with Gleason Score Risk Groups.
    J Urol. 2019;201:278-283.
    PubMed     Text format     Abstract available


    January 2019
  88. BOTEJUE M, Abbott D, Danella J, Fonshell C, et al
    Utilization of Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    J Urol. 2019 Jan 31. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  89. BURNS JF, Hurwitz LM, Levie KE, Caumont F, et al
    Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000024.
    PubMed     Text format     Abstract available


  90. GINSBURG KB, Arcot R, Qi J, Linsell SM, et al
    Confirmatory MRI With or Without Biopsy Impacts Decision-Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000059.
    PubMed     Text format     Abstract available


  91. GOLD SA, Shih JH, Rais-Bahrami S, Bloom JB, et al
    When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion in Prostate Cancer.
    J Urol. 2019 Jan 23. doi: 10.1097/JU.0000000000000112.
    PubMed     Text format     Abstract available


  92. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samartunga H, et al
    Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Po
    J Urol. 2019 Jan 21. doi: 10.1097/JU.0000000000000053.
    PubMed     Text format     Abstract available


  93. SALARI K, Kuppermann D, Preston MA, Dahl DM, et al
    Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years.
    J Urol. 2019 Jan 16. doi: 10.1097/JU.0000000000000031.
    PubMed     Text format     Abstract available


  94. TANEJA SS
    Re: Transcriptomic Heterogeneity in Multifocal Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000101.
    PubMed     Text format    


  95. TANEJA SS
    Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: .
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553310.60445.
    PubMed     Text format    


  96. ATALA A
    Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000096.
    PubMed     Text format    


  97. ZHAO J, Liu J, Sun G, Zhang M, et al
    The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with de Novo Metastatic Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  98. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    J Urol. 2019;201:120-128.
    PubMed     Text format     Abstract available


  99. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
    J Urol. 2019;201:113-119.
    PubMed     Text format     Abstract available


  100. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    J Urol. 2019;201:91-97.
    PubMed     Text format     Abstract available


  101. BLOOM JB, Hale GR, Gold SA, Rayn KN, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
    J Urol. 2019;201:84-90.
    PubMed     Text format     Abstract available


  102. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:33-34.
    PubMed     Text format    


  103. ATALA A
    Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics.
    J Urol. 2019;201:33.
    PubMed     Text format    


  104. TANEJA SS
    Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019;201:31.
    PubMed     Text format    


  105. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2019;201:119.
    PubMed     Text format    


  106. STERNBERG IA
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed     Text format    


  107. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed     Text format    


  108. GLASER ZA, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2019;201:90.
    PubMed     Text format    


  109. PUNNEN S
    Editorial Comment.
    J Urol. 2019;201:83.
    PubMed     Text format    


  110. PERLIS N
    Editorial Comment.
    J Urol. 2019;201:82.
    PubMed     Text format    


  111. SIVARAMAN A, Kim EH, Andriole GL
    Editorial Comment.
    J Urol. 2019;201:112.
    PubMed     Text format    


    December 2018
  112. FRIEDLANDER DF, von Landenberg N, Loppenberg B, Noldus J, et al
    Facility-Level Variation In Rates Of Definitive Therapy For Low-Risk Prostate Cancer Among Men With Limited Life Expectancy: An Opportunity For Value-Based Care Redesign.
    J Urol. 2018 Dec 24. doi: 10.1097/JU.0000000000000006.
    PubMed     Text format     Abstract available


  113. BEKSAC AT, Cumarasamy S, Falagario U, Xu P, et al
    Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    J Urol. 2018;200:1241-1249.
    PubMed     Text format     Abstract available


    November 2018
  114. KRIMPHOVE MJ, Fletcher SA, Cole AP, Berg S, et al
    Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.
    J Urol. 2018 Nov 8. pii: S0022-5347(18)44053-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  115. TANEJA SS
    Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate Cancer.
    J Urol. 2018;200:945-946.
    PubMed     Text format    


  116. TANEJA SS
    Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.
    J Urol. 2018;200:945.
    PubMed     Text format    


  117. TANEJA SS
    Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2018;200:944-946.
    PubMed     Text format    


  118. RESNICK MJ
    Re: Quality of Life during Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Urol. 2018;200:936.
    PubMed     Text format    


    October 2018
  119. CHEN SL, Fann JC, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA).
    J Urol. 2018 Oct 23. pii: S0022-5347(18)44024-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  120. ETHERIDGE T, Liou JI, Downs TM, Abel EJ, et al
    The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43983-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  121. WALTON E, Yaguchi G, Keeley J, Deebajah M, et al
    Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    J Urol. 2018 Oct 11. pii: S0022-5347(18)43980-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  122. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Urol. 2018 Oct 9. pii: S0022-5347(18)43963-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  123. ITO Y, Udo K, Vertosick EA, Sjoberg DD, et al
    Clinical Utility of Prostate and Tumor Volume-Related Parameters Following Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2018 Oct 6. pii: S0022-5347(18)43967-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  124. ATALA A
    Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer.
    J Urol. 2018;200:701-702.
    PubMed     Text format    


  125. TANEJA SS
    Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    J Urol. 2018;200:699.
    PubMed     Text format    


  126. TANEJA SS
    Re: Short-Term Effects of Transdermal Estradiol in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial.
    J Urol. 2018;200:698-699.
    PubMed     Text format    


  127. TANEJA SS
    Re: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    J Urol. 2018;200:697-699.
    PubMed     Text format    


  128. RESNICK MJ
    Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Urol. 2018;200:689.
    PubMed     Text format    


    September 2018
  129. AFSHARI MIRAK S, Shakeri S, Mohammadian Bajgiran A, Felker ER, et al
    3T Multiparametric MRI: Comparison of Performance With and Without Endorectal Coil for Prostate Cancer Detection, PI-RADSv2 Category and Staging with Whole Mount Histopathology Correlation in 429 Patients.
    J Urol. 2018 Sep 28. pii: S0022-5347(18)43960-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  130. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of prostate biopsy with or without pre-biopsy multi-parametric MRI in prostate cancer detection: an observational cohort study.
    J Urol. 2018 Sep 25. pii: S0022-5347(18)43943-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  131. THOMSEN FB, Jakobsen H, Langkilde NC, Borre M, et al
    Active surveillance for localized prostate cancer. Nationwide, observational study.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43911-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  132. LOEB S, Folkvaljon Y, Bratt O, Robinson D, et al
    Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43908-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  133. BALAKRISHNAN AS, Palmer NR, Fergus KB, Gaither TW, et al
    Minority recruitment trends in phase III prostate cancer clinical trials (2003-2014): progress and critical areas for improvement.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43872-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  134. RAJARUBENDRA N, Almeida F, Manojlovic Z, Ohe C, et al
    Histologic Validation of (11)Carbon-Acetate Positron Emission Tomography/Computer Tomography in Detecting Lymph Node Metastases in Prostate Cancer.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43871-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  135. OISHI M, Shin T, Ohe C, Nassiri N, et al
    Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
    J Urol. 2018 Sep 3. pii: S0022-5347(18)43794-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  136. KORNBERG Z, Cowan JE, Westphalen AC, Cooperberg MR, et al
    Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43795-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  137. ANDRIOLE GL, Kostakoglu L, Chau A, Duan F, et al
    The Impact of Positron Emission Tomography with (18)F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43798-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  138. GREGG JR, Lopez DS, Reichard C, Zheng J, et al
    Coffee, Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43796-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  139. ATALA A
    Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer.
    J Urol. 2018;200:501-502.
    PubMed     Text format    


  140. TANEJA SS
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System.
    J Urol. 2018;200:499.
    PubMed     Text format    


  141. TANEJA SS
    Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Urol. 2018;200:498-499.
    PubMed     Text format    


  142. TANEJA SS
    Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological Features.
    J Urol. 2018;200:497-499.
    PubMed     Text format    


  143. RESNICK MJ
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;200:488-489.
    PubMed     Text format    


  144. BOEHM K
    Editorial Comment.
    J Urol. 2018;200:557.
    PubMed     Text format    


  145. BARR RG
    Editorial Comment.
    J Urol. 2018;200:557-558.
    PubMed     Text format    


  146. MARKS LS
    Editorial Comment.
    J Urol. 2018;200:563.
    PubMed     Text format    


  147. LUDVIGSON A, Sammon J
    Editorial Comment.
    J Urol. 2018;200:581.
    PubMed     Text format    


  148. PINTHUS JH
    Editorial Comment.
    J Urol. 2018;200:580.
    PubMed     Text format    


  149. XU AJ, Taksler GB, Llukani E, Lepor H, et al
    Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.
    J Urol. 2018;200:626-632.
    PubMed     Text format     Abstract available


  150. BABALOLA O, Lee TJ, Viviano CJ
    Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information.
    J Urol. 2018;200:512-519.
    PubMed     Text format     Abstract available


  151. GUO DP, Thomas IC, Mittakanti HR, Shelton JB, et al
    The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
    J Urol. 2018;200:541-548.
    PubMed     Text format     Abstract available


    August 2018
  152. BERLIN A, Moraes FY, Sanmamed N, Glicksman R, et al
    International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.
    J Urol. 2018 Aug 25. pii: S0022-5347(18)43782-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  153. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.
    J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  154. LOUGHLIN KR
    Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is not Informative.
    J Urol. 2018 Aug 18. pii: S0022-5347(18)43724-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


  155. DRUSKIN SC, Mamawala M, Tosoian JJ, Epstein JI, et al
    Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    J Urol. 2018 Aug 13. pii: S0022-5347(18)43703-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  156. LOWRANCE WT, Murad MH, Oh WK, Jarrard DF, et al
    Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
    J Urol. 2018 Aug 4. pii: S0022-5347(18)43671-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  157. CRAWFORD ED, Koo PJ, Shore N, Slovin SF, et al
    A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).
    J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  158. DEAN LW, Assel M, Sjoberg DD, Vickers AJ, et al
    Clinical utility of total length Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer.
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43632-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  159. KEARNS JT, Faino AV, Schenk JM, Newcomb LF, et al
    Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS).
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43635-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  160. WINQUIST E
    Editorial Comment.
    J Urol. 2018;200:351-352.
    PubMed     Text format    


  161. SAAD F
    Editorial Comment.
    J Urol. 2018;200:352.
    PubMed     Text format    


  162. STATTIN P
    Editorial Comment.
    J Urol. 2018;200:325-326.
    PubMed     Text format    


  163. LEHRER S
    Editorial Comment.
    J Urol. 2018;200:334.
    PubMed     Text format    


  164. WANG NN, Sonn GA
    Editorial Comment.
    J Urol. 2018;200:318.
    PubMed     Text format    


  165. DOMINGUEZ-ESCRIG JL
    Editorial Comment.
    J Urol. 2018;200:317-318.
    PubMed     Text format    


  166. CRAWFORD ED
    Editorial Comment.
    J Urol. 2018;200:343.
    PubMed     Text format    


  167. JIANG P, Liss MA, Szabo RJ
    Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy.
    J Urol. 2018;200:361-368.
    PubMed     Text format     Abstract available


    July 2018
  168. BLOOM JB, Hale G, Gold SA, Rayn K, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: The Role of a Negative Confirmatory MRI-US Fusion Biopsy.
    J Urol. 2018 Jul 28. pii: S0022-5347(18)43606-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  169. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer-Specific Mortality with Surgery Versus Radiation as Primary Therapy for Localized High-Grade Prostate Cancer in Men Younger than 60 Years Old.
    J Urol. 2018 Jul 27. pii: S0022-5347(18)43599-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  170. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and functional outcome of partial gland ablation with HIFU for localized prostate cancer.
    J Urol. 2018 Jul 20. pii: S0022-5347(18)43550-1. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  171. GOVERS T, Caba L, Resnick MJ
    Cost-Effectiveness of SelectMDx in Prostate Cancer Risk Assessment.
    J Urol. 2018 Jul 13. pii: S0022-5347(18)43530-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  172. TRUONG M
    Editorial Comment.
    J Urol. 2018;200:113.
    PubMed     Text format    


  173. CARLSSON S
    Editorial Comment.
    J Urol. 2018;200:87.
    PubMed     Text format    


  174. RESNICK MJ
    Editorial Comment.
    J Urol. 2018;200:80-81.
    PubMed     Text format    


  175. HUEN KH, Bergman J
    Editorial Comment.
    J Urol. 2018;200:80.
    PubMed     Text format    


  176. ROSENKRANTZ AB, Hemingway J, Hughes DR, Duszak R Jr, et al
    Evolving Use of Prebiopsy Prostate Magnetic Resonance Imaging in the Medicare Population.
    J Urol. 2018;200:89-94.
    PubMed     Text format     Abstract available


  177. GORDETSKY JB, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2018;200:112-113.
    PubMed     Text format    


  178. BHINDI B, Wallis CJD
    Editorial Comment.
    J Urol. 2018;200:125.
    PubMed     Text format    


  179. BAYNE CE
    Re: Missed Opportunities to Decrease Radiation Exposure in Children with Renal Trauma: T. W. Gaither, M. A. Awad, N. V. Leva, G. P. Murphy, B. N. Breyer and H. L. Copp J Urol 2018;199:552-557.
    J Urol. 2018;200:205-206.
    PubMed     Text format    


  180. SCIALPI M, D'Andrea A, Aisa MC, Malaspina CM, et al
    Re: Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: T. Ullrich, M. Quentin, C. Arsov, A. K. Schmaltz, A. Tschischka, N. Laqua, A. Hiester, D. Blondin, R. Rabenalt, P. Albers, G. Antoch and L. Sch
    J Urol. 2018;200:202-204.
    PubMed     Text format    


    June 2018
  181. RICHARDS KA, Liou JI, Cryns VL, Downs TM, et al
    Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  182. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Preisser F, et al
    Anterior localization of prostate cancer suspicious MRI lesions in patients undergoing initial and repeat biopsy: Results from 1,161 patients undergoing MRI/ultrasound fusion-guided targeted biopsies.
    J Urol. 2018 Jun 20. pii: S0022-5347(18)43405-2. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  183. MARZOUK K, Assel M, Ehdaie B, Vickers A, et al
    Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort.
    J Urol. 2018 Jun 7. pii: S0022-5347(18)43349-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  184. LEPPERT JT, Asch SM, Bergman J
    Ethical Pitfalls When Estimating Life Expectancy For Patients with Prostate Cancer.
    J Urol. 2018 Jun 6. pii: S0022-5347(18)43328-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


  185. TANEJA SS
    Re: Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-Effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    J Urol. 2018;199:1397-1398.
    PubMed     Text format    


  186. TANEJA SS
    Re: Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Urol. 2018;199:1396-1398.
    PubMed     Text format    


  187. GRIEBLING TL
    Re: Potential Overtreatment among Men Aged 80 Years and Older with Localized Prostate Cancer in Japan.
    J Urol. 2018;199:1375.
    PubMed     Text format    


  188. GRIEBLING TL
    Re: Safety and Feasibility of Robot-Assisted Radical Prostatectomy for Clinically Localized Prostate Cancer in Elderly Japanese Patients.
    J Urol. 2018;199:1375-1376.
    PubMed     Text format    


  189. GRIEBLING TL
    Re: Long-Term Survival of Patients Aged 80 Years or Older Treated with Radical Prostatectomy for Prostate Cancer.
    J Urol. 2018;199:1374.
    PubMed     Text format    


  190. GRIEBLING TL
    Re: Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    J Urol. 2018;199:1373-1376.
    PubMed     Text format    


  191. GILL IS, Azzouzi AR, Emberton M, Coleman JA, et al
    Randomized Trial of Partial Gland Ablation with Vascular-Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness.
    J Urol. 2018 Jun 1. pii: S0022-5347(18)43299-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    May 2018
  192. RAYN KN, Bloom JB, Gold SA, Hale GR, et al
    Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer.
    J Urol. 2018 May 28. pii: S0022-5347(18)43271-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  193. WEINER AB, Tsai KP, Keeter MK, Victorson DE, et al
    The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.
    J Urol. 2018 May 28. pii: S0022-5347(18)43270-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  194. AMINSHARIFI A, Howard L, Wu Y, De Hoedt A, et al
    Prostate-specific antigen density as a predictor of clinically significant prostate cancer when the PSA level is in the diagnostic "grey-zone": Defining the optimum cut-point stratified by race and body mass index.
    J Urol. 2018 May 11. pii: S0022-5347(18)43126-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  195. HOFBAUER SL, Kittner B, Maxeiner A, Heckmann R, et al
    Validation of PI-RADS version 2 for the detection of prostate cancer.
    J Urol. 2018 May 4. pii: S0022-5347(18)43099-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  196. CRAWFORD ED, Schellhammer PF, McLeod DG, Moul JW, et al
    Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens.
    J Urol. 2018 May 3. pii: S0022-5347(18)43086-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  197. TANEJA SS
    Re: Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-Deficient Prostate Cancer.
    J Urol. 2018;199:1113.
    PubMed     Text format    


  198. TANEJA SS
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;199:1112-1113.
    PubMed     Text format    


  199. SIEGEL C
    Re: Role of MRI in the Use of an Absorbable Hydrogel Spacer in Men Undergoing Radiation Therapy for Prostate Cancer: What the Radiologist Needs to Know.
    J Urol. 2018;199:1092.
    PubMed     Text format    


    April 2018
  200. RAVI P, Karnes RJ, Rangel LJ, Pagliaro LC, et al
    Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    J Urol. 2018 Apr 27. pii: S0022-5347(18)43071-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  201. LARSEN LK, Jakobsen JS, Abdul-Al A, Guldberg P, et al
    Noninvasive detection of high-grade prostate cancer by DNA-methylation analysis of urine cells captured by microfiltration.
    J Urol. 2018 Apr 24. pii: S0022-5347(18)43047-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  202. PATEL HD, Gupta M, Tosoian JJ, Carter HB, et al
    Subtyping the Risk of Intermediate-Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  203. GILD P, Cole AP, Krasnova A, Dickerman BA, et al
    Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42984-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  204. RYAN CJ, Crawford ED, Shore ND, Underwood W 3rd, et al
    The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2018 Apr 6. pii: S0022-5347(18)42900-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  205. ATALA A
    Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.
    J Urol. 2018;199:895-896.
    PubMed     Text format    


  206. TANEJA SS
    Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Urol. 2018;199:893-894.
    PubMed     Text format    


  207. TANEJA SS
    Re: Health-Related Quality of Life for Immediate versus Delayed Androgen-Deprivation Therapy in Patients with Asymptomatic, Non-Curable Prostate Cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): A Randomised, Multicentre, Non-Blinded, Phase 3 Trial.
    J Urol. 2018;199:892-894.
    PubMed     Text format    


  208. CADEDDU JA
    Re: Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for 'Node-Only' Recurrent Prostate Cancer: Technique and Initial Series.
    J Urol. 2018;199:875-876.
    PubMed     Text format    


  209. SIEGEL C
    Re: Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
    J Urol. 2018;199:873.
    PubMed     Text format    


    March 2018
  210. WEI C, Li C, Szewczyk-Bieda M, Upreti D, et al
    Performance characteristics of transrectal shear wave elastography (SWE) imaging in the evaluation of clinically localised prostate cancer: a prospective study.
    J Urol. 2018 Mar 29. pii: S0022-5347(18)42856-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  211. SHAH N, Ioffe V
    Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
    J Urol. 2018 Mar 26. pii: S0022-5347(18)42402.
    PubMed     Text format    


  212. PATEL N, Hu JC
    Re: Recent Changes in Prostate Cancer Screening Practices and Epidemiology: D. J. Lee, K. Mallin, A. J. Graves, S. S. Chang, D. F. Penson, M. J. Resnick and D. A. Barocas J Urol 2017;198:1230-1240.
    J Urol. 2018 Mar 16. pii: S0022-5347(18)30117-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


  213. KLOTZ L, Loblaw A, Siemens R, Ouellette P, et al
    A phase II, randomized, multicentre study comparing 10 months versus 4 months of degarelix (Firmagon(R)) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for bio
    J Urol. 2018 Mar 10. pii: S0022-5347(18)42502-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  214. RANDALL S, Boyd J, Fuller E, Brooks C, et al
    The effect of vasectomy reversal on prostate cancer risk: International meta-analysis of 684,660 men with vasectomies.
    J Urol. 2018 Mar 7. pii: S0022-5347(18)42489-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  215. PATEL N, Halpern JA, Kasabwala K, Cricco-Lizza E, et al
    Multiple regions of interest on multi-parametric magnetic resonance imaging are not associated with increased detection of clinically significant prostate cancer on fusion biopsy.
    J Urol. 2018 Mar 5. pii: S0022-5347(18)42470-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    February 2018
  216. VAN STAM MA, Pieterse AH, van der Poel HG, Bosch JLHR, et al
    Shared Decision-Making in Prostate Cancer Care: Encouraging every patient to be actively involved in decision-making, or ensuring patients' preferred level of involvement?
    J Urol. 2018 Feb 28. pii: S0022-5347(18)42403.
    PubMed     Text format     Abstract available


  217. SAMPURNO F, Zheng J, Di Stefano L, Millar JL, et al
    Quality indicators for global benchmarking of localised prostate cancer management.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39377-7. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  218. MARZOUK S, Naglie G, Tomlinson G, Duff Canning S, et al
    Impact of Androgen Deprivation Therapy on Self-reported Cognitive Function in Men with Prostate Cancer.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39379-0. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  219. MORTEZAVI A, Marzendorfer O, Donati OF, Rizzi G, et al
    Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
    J Urol. 2018 Feb 20. pii: S0022-5347(18)39373-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  220. BAPAT B
    Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Lobl
    J Urol. 2018 Feb 8. pii: S0022-5347(18)30001-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  221. OZGUR BC
    Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
    J Urol. 2018 Feb 8. pii: S0022-5347(17)78117-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  222. NABHANI JA, Kuang R, Liu H, Kwan L, et al
    Health Changes in Low-income Men Transitioning from a State-funded Prostate Cancer Program to Comprehensive Insurance.
    J Urol. 2018 Feb 6. pii: S0022-5347(18)30183-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  223. ATALA A
    Re: mTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer.
    J Urol. 2018;199:344-346.
    PubMed     Text format    


  224. TANEJA SS
    Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
    J Urol. 2018;199:342-343.
    PubMed     Text format    


  225. SEFTEL AD
    Re: The Accuracy of Patients' Perceptions of the Risks Associated with Localised Prostate Cancer Treatments.
    J Urol. 2018;199:329.
    PubMed     Text format    


  226. SIEGEL C
    Re: Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience with 101 Patients.
    J Urol. 2018;199:325.
    PubMed     Text format    


  227. SUN M, Cole AP, Hanna N, Mucci LA, et al
    Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
    J Urol. 2018 Feb 1. pii: S0022-5347(18)30109-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    January 2018
  228. LOPCI E, Saita A, Lazzeri M, Lughezzani G, et al
    (68)Ga-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI: a prospective observational study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30172-1. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  229. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Long-term outcome of a single intervention Population based Prostate Cancer Screening Study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30173-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  230. PRENDEVILLE S, Gertner M, Maganti M, Pintilie M, et al
    Role of MRI-targeted Biopsy in Detection of Prostate Cancer Harbouring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30175-7. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  231. LEE JS, Lee HS, Ha JS, Han KS, et al
    Subcutaneous fat distribution is a prognostic biomarker for men with castration-resistant prostate cancer.
    J Urol. 2018 Jan 20. pii: S0022-5347(18)30106-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  232. CHALFIN HJ, Glavaris SA, Malihi PD, Sperger JM, et al
    Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Localized Patients Undergoing Radical Prostatectomy Across Multiple Rare Cell Detection Platforms.
    J Urol. 2018 Jan 12. pii: S0022-5347(18)30065-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  233. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
    J Urol. 2018 Jan 10. pii: S0022-5347(18)30014-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


  234. NGUYEN DP, Vertosick EA, Sharma V, Corradi RB, et al
    Does subclassification of pathologically organ-confined (pT2) prostate cancer provide prognostic discrimination of outcomes after radical prostatectomy?
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30005-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  235. KAPLAN SA
    Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    J Urol. 2018;199:7-8.
    PubMed     Text format    


  236. TANEJA SS
    Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    J Urol. 2018;199:28.
    PubMed     Text format    


  237. TANEJA SS
    Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2018;199:26-28.
    PubMed     Text format    


  238. PENSON DF
    Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Urol. 2018;199:19-20.
    PubMed     Text format    


  239. CADEDDU JA
    Re: Near-Infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer.
    J Urol. 2018;199:13-14.
    PubMed     Text format    


  240. SALAMI SS
    Editorial Comment.
    J Urol. 2018;199:104.
    PubMed     Text format    


  241. SONN G
    Editorial Comment.
    J Urol. 2018;199:104-105.
    PubMed     Text format    


  242. GHANI KR, Miller DC, Montie JE
    Editorial Comment.
    J Urol. 2018;199:96-97.
    PubMed     Text format    


  243. JOHNSON DC, Litwin MS
    Editorial Comment.
    J Urol. 2018;199:96.
    PubMed     Text format    


  244. PATEL NA, Kasabwala K, Hu JC
    Editorial Comment.
    J Urol. 2018;199:138-139.
    PubMed     Text format    


  245. NAHAR B, Parekh DJ
    Editorial Comment.
    J Urol. 2018;199:138.
    PubMed     Text format    


  246. BHINDI B
    Editorial Comment.
    J Urol. 2018;199:87-88.
    PubMed     Text format    


  247. KAPOOR DA
    A History of the United States Preventive Services Task Force: Its Expanding Authority and Need for Reform.
    J Urol. 2018;199:37-39.
    PubMed     Text format    


  248. TETREAULT-LAFLAMME A, Crook J, Hamm J, Pickles T, et al
    Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    J Urol. 2018;199:120-125.
    PubMed     Text format     Abstract available


  249. LUDWIG WW, Feng Z, Trock BJ, Humphreys E, et al
    Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    J Urol. 2018;199:114-119.
    PubMed     Text format     Abstract available


    December 2017
  250. OROM H, Biddle C, Underwood W 3rd, Nelson CJ, et al
    Worse urinary, sexual, and bowel function cause emotional distress and vice versa in men treated for prostate cancer.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78180-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  251. BERNSTEIN AN, Shoag JE, Golan R, Halpern JA, et al
    Contemporary Incidence & Outcomes of Prostate Cancer Lymph Node Metastases.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78181-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  252. AGHAZADEH MA, Frankel J, Belanger M, McLaughlin T, et al
    NCCN Favorable Intermediate Risk Prostate Cancer Patients: Is Active Surveillance Appropriate?
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78182-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  253. LIU RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, et al
    Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78068-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  254. VASAVADA SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, et al
    Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78097-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  255. GEARMAN DJ, Morlacco A, Cheville JC, Rangel LJ, et al
    Comparison of Pathological and Oncologic Outcomes in "Favorable Risk" GS 3+4 and Low Risk GS6 Prostate Cancer: Considerations for Active Surveillance.
    J Urol. 2017 Dec 7. pii: S0022-5347(17)78036-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  256. ATALA A
    Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer.
    J Urol. 2017;198:1213.
    PubMed     Text format    


  257. ATALA A
    Re: The Metabolic Co-Regulator PGC1alpha Suppresses Prostate Cancer Metastasis.
    J Urol. 2017;198:1212-1214.
    PubMed     Text format    


  258. TANEJA SS
    Re: Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis and Response to Androgen Deprivation Therapy.
    J Urol. 2017;198:1211.
    PubMed     Text format    


  259. TANEJA SS
    Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    J Urol. 2017;198:1210-1211.
    PubMed     Text format    


  260. TANEJA SS
    Re: Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Urol. 2017;198:1209-1210.
    PubMed     Text format    


  261. TANEJA SS
    Re: Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    J Urol. 2017;198:1208-1211.
    PubMed     Text format    


  262. MOREY AF
    Re: Radiation-Induced Complex Anterior Urinary Fistulation for Prostate Cancer: A Retrospective Multicenter Study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS).
    J Urol. 2017;198:1201-1203.
    PubMed     Text format    


  263. PENSON DF
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:1200.
    PubMed     Text format    


  264. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78003-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    November 2017
  265. HASSAN O, Han M, Zhou A, Paulk A, et al
    Incidence of Extra-Prostatic Extension at Radical Prostatectomy with Pure Gleason Score 3+3=6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed as "not Cancer" and for Selection Criteria for Active Surv
    J Urol. 2017 Nov 15. pii: S0022-5347(17)77915-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  266. PISHGAR F, Ebrahimi H, Moghaddam SS, Fitzmaurice C, et al
    Global, Regional and National Burden of Prostate Cancer, 1990 - 2015: Results from the Global Burden of Disease Study 2015.
    J Urol. 2017 Nov 9. pii: S0022-5347(17)77883-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  267. TANEJA SS
    Re: Weight Change, Obesity and Risk of Prostate Cancer Progression among Men with Clinically Localized Prostate Cancer.
    J Urol. 2017;198:982.
    PubMed     Text format    


  268. TANEJA SS
    Re: Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer.
    J Urol. 2017;198:982-983.
    PubMed     Text format    


  269. TANEJA SS
    Re: Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with National Comprehensive Cancer Network Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    J Urol. 2017;198:981.
    PubMed     Text format    


  270. TANEJA SS
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:980-983.
    PubMed     Text format    


    October 2017
  271. HALPERN JA, Oromendia C, Shoag JE, Mittal S, et al
    Utility of Digital Rectal Examination (DRE) as an Adjunct to Prostate Specific Antigen (PSA) in the Detection of Clinically Significant Prostate Cancer.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77762-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  272. AUDENET F, Vertosick EA, Fine SW, Sjoberg DD, et al
    Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77714-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  273. ATALA A
    Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer.
    J Urol. 2017;198:747.
    PubMed     Text format    


  274. TANEJA SS
    Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer.
    J Urol. 2017;198:745.
    PubMed     Text format    


  275. PENSON DF
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:744-745.
    PubMed     Text format    


  276. TANEJA SS
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:743-744.
    PubMed     Text format    


  277. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    J Urol. 2017;198:742-743.
    PubMed     Text format    


  278. TANEJA SS
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    J Urol. 2017;198:741-745.
    PubMed     Text format    


  279. PENSON DF
    Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men.
    J Urol. 2017;198:734-735.
    PubMed     Text format    


  280. GRIEBLING TL
    Re: Current Impact of Age and Comorbidity Assessment on Prostate Cancer Treatment Choice and Over/Undertreatment Risk.
    J Urol. 2017;198:724.
    PubMed     Text format    


  281. GRIEBLING TL
    Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    J Urol. 2017;198:723.
    PubMed     Text format    


  282. GRIEBLING TL
    Re: Which Better Predicts Mortality among Older Men, a Prostate Cancer (PCa) Diagnosis or Vulnerability on the Vulnerable Elders Survey (VES-13)? A Retrospective Cohort Study.
    J Urol. 2017;198:723-724.
    PubMed     Text format    


    September 2017
  283. HOUSTON KA, King J, Li J, Jemal A, et al
    Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate-Specific Antigen Screening by Socioeconomic Status and Regions in the US, 2004- 2013.
    J Urol. 2017 Sep 28. pii: S0022-5347(17)77650-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  284. HEILBRUN LK, Powell IJ
    Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. T
    J Urol. 2017 Sep 26. pii: S0022-5347(17)77419-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  285. TOSOIAN JJ, Carter HB
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77388-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  286. SANDA MG
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77389-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  287. XU X, Zhang X, Zhong Y, Saad F, et al
    Dynamic Patterns of Testosterone Levels within Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77561-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  288. NGUYEN HG, Welty C, Lindquist K, Ngo V, et al
    Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77554-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  289. SHIOTA M, Fujimoto N, Takeuchi A, Kashiwagi E, et al
    The association of polymorphisms in the gene encoding gonadotropin releasing hormone with serum testosterone level during androgen-deprivation therapy and prognosis in metastatic prostate cancer.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77562-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  290. NYAME YA, Grimberg DC, Greene DJ, Gupta K, et al
    Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77563-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  291. GARCIA-REYES K, Nguyen HG, Zagoria RJ, Shinohara K, et al
    Impact of lesion visibility on transrectal ultrasound on the prediction of clinically significant prostate cancer (Gleason score >/= 3+4) with TRUS-MRI fusion biopsy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77560-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  292. NEHRA A, Parker WP, Haloi R, Park SS, et al
    Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic MRI.
    J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  293. ORCZYK C, Emberton M
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 Sep 6. pii: S0022-5347(17)77256-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  294. ATALA A
    Re: MicroRNA-141 Suppresses Prostate Cancer Stem Cells and Metastasis by Targeting a Cohort of Pro-Metastasis Genes.
    J Urol. 2017;198:486.
    PubMed     Text format    


  295. ATALA A
    Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
    J Urol. 2017;198:485-487.
    PubMed     Text format    


  296. TANEJA SS
    Re: Videotaping of Surgical Procedures and Outcomes following Extraperitoneal Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer.
    J Urol. 2017;198:483-484.
    PubMed     Text format    


  297. SEFTEL AD
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:466-468.
    PubMed     Text format    


  298. TEETER AE, Griffin K, Howard LE, Aronson WJ, et al
    Does early PSADT (ePSADT) after Radical Prostatectomy, Calculated prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? -A Report from the SEARCH Database Group.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    August 2017
  299. TOMBAL B, Borre M, Rathenborg P, Werbrouck P, et al
    Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 3-year, Open-label, Follow-up Results.
    J Urol. 2017 Aug 31. pii: S0022-5347(17)77422-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  300. CASTELLO A, Boldo E, Amiano P, Castano-Vinyals G, et al
    Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study.
    J Urol. 2017 Aug 22. pii: S0022-5347(17)77385-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  301. SIEMENS DR, Klotz L, Heidenreich A, Chowdhury S, et al
    Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial.
    J Urol. 2017 Aug 18. pii: S0022-5347(17)77377-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  302. GARCIA-BARRERAS S, Sanchez-Salas R, Sivaraman A, Barret E, et al
    Partial gland ablation versus radical prostatectomy Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low- and Intermediate-risk Prostate Cancer: Oncologic and Functional Outcomes.
    J Urol. 2017 Aug 17. pii: S0022-5347(17)77373-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  303. SHRESTHA E, White JR, Yu SH, Kulac I, et al
    Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.
    J Urol. 2017 Aug 7. pii: S0022-5347(17)77253-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  304. DAI C, Ganesan V, Zabell J, Nyame YA, et al
    Impact of 5alpha-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features.
    J Urol. 2017 Aug 5. pii: S0022-5347(17)77259-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  305. AUFFENBERG GB, Lane BR, Linsell S, Brachulis A, et al
    A Roadmap for improving the management of men with favorable-risk prostate cancer.
    J Urol. 2017 Aug 3. pii: S0022-5347(17)77250-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  306. ATALA A
    Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer.
    J Urol. 2017;198:259.
    PubMed     Text format    


  307. TANEJA SS
    Re: Change in Salvage Radiotherapy Management Based on Guidance with FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
    J Urol. 2017;198:256-257.
    PubMed     Text format    


  308. TANEJA SS
    Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.
    J Urol. 2017;198:255-257.
    PubMed     Text format    


    July 2017
  309. SAMMON JD, Serrell EC, Karabon P, Leow JJ, et al
    Prostate Cancer Screening in Early Medicaid Expansion States.
    J Urol. 2017 Jul 29. pii: S0022-5347(17)77241-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  310. TAPLIN ME, Armstrong AJ, Lin P, Krivoshik A, et al
    Clinical Outcomes of Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77187-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  311. TAMMELA TL, Haggman M, Ladjevardi S, Taari K, et al
    An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77188-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  312. GORIN MA, Rowe SP, Patel HD, Vidal I, et al
    PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77186-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  313. CHANG E, Jones TA, Natarajan S, Sharma D, et al
    Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77144-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  314. YANG L, Kibel AS, Colditz GA, Pakpahan R, et al
    Caution with Use of the Expanded Prostate Cancer Index Composite-50 Urinary Bother Scale: How Voiding Dysfunction Modifies Its Performance.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77147-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  315. STROUP SP, Moreira DM, Chen Z, Howard L, et al
    Biopsy-Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis, and Mortality in a Cohort of Men with High-Risk Prostate Cancer.
    J Urol. 2017 Jul 11. pii: S0022-5347(17)77098-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  316. PENSON DF
    Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
    J Urol. 2017;198:104-105.
    PubMed     Text format    


  317. PENSON DF
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Urol. 2017;198:104-106.
    PubMed     Text format    


  318. ATALA A
    Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer.
    J Urol. 2017;198:103-104.
    PubMed     Text format    


  319. ATALA A
    Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
    J Urol. 2017;198:103.
    PubMed     Text format    


  320. ATALA A
    Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance.
    J Urol. 2017;198:102-104.
    PubMed     Text format    


  321. TANEJA SS
    Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    J Urol. 2017;198:101-102.
    PubMed     Text format    


  322. TANEJA SS
    Re: Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    J Urol. 2017;198:100-102.
    PubMed     Text format    


    June 2017
  323. BHINDI B, Karnes RJ, Rangel LJ, Mason RJ, et al
    Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
    J Urol. 2017 Jun 29. pii: S0022-5347(17)77027-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  324. JONES TA, Chin J, Mcleod D, Barkin J, et al
    High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial.
    J Urol. 2017 Jun 23. pii: S0022-5347(17)76734-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  325. PALAPATTU GS
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  326. PUNNEN S, Parekh DJ
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67197-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  327. KIBEL AS
    Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  328. SEFTEL AD
    Re: Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    J Urol. 2017;197:1534-1535.
    PubMed     Text format    


  329. KAPLAN SA
    Re: Interactions between Benign Prostatic Hyperplasia (BPH) and Prostate Cancer in Large Prostates: A Retrospective Data Review.
    J Urol. 2017;197:1531-1532.
    PubMed     Text format    


  330. ATALA A
    Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse.
    J Urol. 2017;197:1459.
    PubMed     Text format    


  331. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:1458-1459.
    PubMed     Text format    


  332. CADEDDU JA
    Re: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    J Urol. 2017;197:1457-1458.
    PubMed     Text format    


  333. TANEJA SS
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:1456.
    PubMed     Text format    


  334. TANEJA SS
    Re: Mortality among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    J Urol. 2017;197:1456-1457.
    PubMed     Text format    


  335. DENIZE J, Nouhaud FX, Cornu JN, Pfister C, et al
    Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R.
    J Urol. 2017 Jun 1. pii: S0022-5347(17)59378-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    May 2017
  336. YAN W, Shang Z, Zhou Z
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 May 31. pii: S0022-5347(17)57834-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  337. TELOKEN PE, Li J, Woods CG, Cohen RJ, et al
    The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure.
    J Urol. 2017 May 26. pii: S0022-5347(17)74541-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  338. TOMBAL B, Cornel EB, Persad R, Stari A, et al
    Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    J Urol. 2017 May 25. pii: S0022-5347(17)74503-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  339. FELDMAN AS, Meyer CP, Sanchez A, Krasnova A, et al
    Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population-Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    J Urol. 2017 May 25. pii: S0022-5347(17)74504-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  340. LEE DJ, Mallin K, Graves AJ, Chang SS, et al
    Recent changes in prostate cancer screening practices and prostate cancer epidemiology.
    J Urol. 2017 May 25. pii: S0022-5347(17)74517-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  341. HENRY MA, Howard DH, Davies BJ, Filson CP, et al
    Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.
    J Urol. 2017 May 6. pii: S0022-5347(17)64683-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  342. SEFTEL AD
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1266.
    PubMed     Text format    


  343. TANEJA SS
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1265-1266.
    PubMed     Text format    


  344. TANEJA SS
    Re: Development and Validation of a 24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer: A Matched, Retrospective Analysis.
    J Urol. 2017;197:1264-1266.
    PubMed     Text format    


    April 2017
  345. GOLAN R, Bernstein AN, McClure TD, Sedrakyan A, et al
    Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54786-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  346. NATARAJAN S, Jones TA, Priester AM, Geoghegan R, et al
    Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance.
    J Urol. 2017 Apr 7. pii: S0022-5347(17)45433-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    March 2017
  347. DISTLER FA, Radtke JP, Bonekamp D, Kesch C, et al
    The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43846-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  348. MEHRALIVAND S, Bednarova S, Shih JH, Mertan FV, et al
    Prospective Evaluation of Prostate Imaging-Reporting and Data System Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43847-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  349. NYAME YA, Almassi N, Haywood SC, Greene DJ, et al
    Intermediate-Term Outcomes of Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    J Urol. 2017 Mar 24. pii: S0022-5347(17)42185-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  350. LEBDAI S, Bigot P, Leroux PA, Berthelot LP, et al
    Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.
    J Urol. 2017 Mar 18. pii: S0022-5347(17)40346-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    February 2017
  351. TANEJA SS
    Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer.
    J Urol. 2017;197:398-399.
    PubMed     Text format    


    December 2016
  352. KAPLAN SA
    Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease.
    J Urol. 2016;196:1713-1714.
    PubMed     Text format    


    June 2016
  353. KAPLAN SA
    Re: Resveratrol Reduces the Levels of Circulating Androgen Precursors but has No Effect on Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomised Trial in Middle-Aged Men.
    J Urol. 2016;195:1838.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: